Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Am Coll Cardiol ; 41(12): 2119-25, 2003 Jun 18.
Article in English | MEDLINE | ID: mdl-12821234

ABSTRACT

OBJECTIVES: The purpose of this study was to assess the safety and efficacy of the oral prostacyclin analogue beraprost sodium during a 12-month double-blind, randomized, placebo-controlled trial in patients with pulmonary arterial hypertension (PAH). BACKGROUND: Pulmonary arterial hypertension is a progressive disease that ultimately causes right heart failure and death. Despite the risks from its delivery system, continuous intravenous epoprostenol remains the most efficacious treatment currently available. METHODS: A total of 116 patients with World Health Organization (WHO) functional class II or III primary pulmonary hypertension or PAH related to either collagen vascular diseases or congenital systemic to pulmonary shunts were enrolled. Patients were randomized to receive the maximal tolerated dose of beraprost sodium (median dose 120 microg four times a day) or placebo for 12 months. The primary end point was disease progression; i.e., death, transplantation, epoprostenol rescue, or >25% decrease in peak oxygen consumption (VO(2)). Secondary end points included exercise capacity assessed by 6-min walk test and peak VO(2), Borg dyspnea score, hemodynamics, symptoms of PAH, and quality of life. RESULTS: Patients treated with beraprost exhibited less evidence of disease progression at six months (p = 0.002), but this effect was not evident at either shorter or longer follow-up intervals. Similarly, beraprost-treated patients had improved 6-min walk distance at 3 months by 22 m from baseline and at 6 months by 31 m (p = 0.010 and 0.016, respectively) compared with placebo, but not at either 9 or 12 months. Drug-related adverse events were common and were related to the disease and/or expected prostacyclin adverse events. CONCLUSIONS: These data suggest that beneficial effects may occur during early phases of treatment with beraprost in WHO functional class II or III patients but that this effect attenuates with time.


Subject(s)
Epoprostenol/analogs & derivatives , Epoprostenol/administration & dosage , Epoprostenol/therapeutic use , Hypertension, Pulmonary/drug therapy , Vasodilator Agents/administration & dosage , Vasodilator Agents/therapeutic use , Administration, Oral , Adult , Dose-Response Relationship, Drug , Double-Blind Method , Drug Administration Schedule , Epoprostenol/adverse effects , Exercise Tolerance/drug effects , Exercise Tolerance/physiology , Female , Follow-Up Studies , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Hypertension, Pulmonary/physiopathology , Male , Quality of Life , Severity of Illness Index , Tablets , Time Factors , Vasodilator Agents/adverse effects
2.
J Cardiovasc Pharmacol ; 41(2): 293-9, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12548091

ABSTRACT

Intravenous epoprostenol is currently FDA approved for management of primary pulmonary hypertension, but it requires intravenous infusion and is associated with adverse effects. The objective of this study was to evaluate the effects of an epoprostenol analog, treprostinil, for management of pulmonary hypertension. Ten tertiary care academic institutions with pulmonary hypertension programs participated in these pilot trials. In the first trial, intravenous epoprostenol and intravenous treprostinil were compared. In the second trial, intravenous treprostinil and subcutaneous treprostinil were compared. In the third trial, subcutaneous treprostinil was compared with placebo infusion during an 8-week period. Intravenous epoprostenol and intravenous treprostinil resulted in a similar reduction in pulmonary vascular resistance acutely (22% and 20%, respectively). Intravenous treprostinil and subcutaneous treprostinil also demonstrated comparable short-term decrease in pulmonary vascular resistance (23% and 28%, respectively). The placebo-controlled 8-week trial demonstrated a mean improvement of 37 +/- 17 m as measured by the 6-minute walk distance in patients receiving treprostinil compared with a 6 +/- 28 m reduction in those receiving placebo. There were trends toward an improvement in cardiac index and pulmonary vascular resistance index in the treprostinil group. Subcutaneous treprostinil has favorable hemodynamic effects when given acutely and in the short term. Treprostinil can be given safely to an ambulatory patient with a novel subcutaneous delivery pump system.


Subject(s)
Epoprostenol/analogs & derivatives , Epoprostenol/administration & dosage , Epoprostenol/adverse effects , Hypertension, Pulmonary/drug therapy , Adolescent , Adult , Aged , Analysis of Variance , Child , Epoprostenol/chemistry , Female , Hemodynamics/drug effects , Hemodynamics/physiology , Humans , Hypertension, Pulmonary/physiopathology , Male , Middle Aged , Statistics, Nonparametric
SELECTION OF CITATIONS
SEARCH DETAIL
...